Biodexa Pharmaceuticals (BDRX) Finished Goods (2015 - 2017)

Biodexa Pharmaceuticals has disclosed Finished Goods across 3 years of filings, most recently posting $1.2 million for Q4 2017.

• In Q4 2017, Finished Goods rose 23.0% year-over-year to $1.2 million; the TTM figure through Dec 2017 stood at $1.2 million (up 23.0% YoY), while the FY2017 annual figure was $1.2 million, up 9.37% from the prior year.
• Finished Goods came in at $1.2 million for Q4 2017 at Biodexa Pharmaceuticals, up from $1.0 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $1.2 million in Q4 2017 to a low of $347505.3 in Q4 2015.
• Average Finished Goods over 3 years is $870850.2, with a median of $1.0 million recorded in 2016.
• Year-over-year, Finished Goods jumped 192.29% in 2016 and rose 23.0% in 2017.
• Over 3 years, Finished Goods stood at $347505.3 in 2015, then jumped by 192.29% to $1.0 million in 2016, then gained by 23.0% to $1.2 million in 2017.
• Per Business Quant data, the three most recent Finished Goods figures were $1.2 million in Q4 2017, $1.0 million in Q4 2016, and $347505.3 in Q4 2015.